氯法齐明在妊娠及产后耐多药结核女性中的药代动力学与安全性
妊娠期暴露与非妊娠历史数据相当,但产后暴露低于妊娠晚期约 30%;严重不良事件与氯法齐明直接相关性被认为不太可能。
要点
- 妊娠期氯法齐明暴露与非妊娠女性历史数据相当。
- 产后暴露较妊娠晚期低约 30%,需关注剂量充分性。
- 严重不良事件与氯法齐明直接相关性被认为不太可能。
核心结论
- 妊娠期和产后氯法齐明暴露总体与非妊娠耐利福平结核女性报告值相当。
- 产后暴露低于预期,尤其与妊娠晚期相比。
研究设计与样本
- IMPAACT P1026s 为观察性研究,评估妊娠期结核和/或抗逆转录病毒药物药代动力学。
- 采用非房室法估算药代动力学参数,用几何均值比(GMR)及 90% 置信区间(CI)和配对 Wilcoxon 符号秩检验比较产前与产后。
主要发现
- 9 名(82%)女性产后继续治疗。
- 峰浓度和 12 小时药时曲线下面积与非妊娠耐利福平结核女性历史数据相当,但妊娠晚期较产后高约 30%。
- 8 名女性和 8 名婴儿在研究期间经历至少一次严重不良事件,但与氯法齐明直接相关性被认为不太可能。
临床怎么用
- 妊娠期氯法齐明 100 mg 每日暴露与非妊娠历史数据相当,可支持该剂量在妊娠期使用。
- 产后暴露较妊娠晚期低约 30%,临床应关注产后治疗剂量充分性及疗效监测。
局限性
- 产后采样仅 2–8 周,未覆盖更长期暴露。
- 严重不良事件与氯法齐明直接相关性评估为主观判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are no published data on clofazimine pharmacokinetics during pregnancy, and safety data are limited. We present data from pregnant and postpartum women receiving clofazimine for treatment of rifampicin-resistant tuberculosis (RR-TB). METHODS: IMPAACT P1026s was an observational study to assess the pharmacokinetics of tuberculosis and/or antiretroviral drugs during pregnancy. Between 2017 and 2019, pregnant women receiving ≥2 second-line antituberculosis drugs in routine care were enrolled in the second or third trimester and had intensive pharmacokinetic sampling at least once during pregnancy, and 2-8 weeks postpartum. Pharmacokinetic parameters were estimated using noncompartmental methods and compared between the antepartum and postpartum periods using geometric mean ratios (GMR) with 90% confidence intervals (CIs) and the Wilcoxon signed rank test for paired data. RESULTS: Eleven pregnant women from South Africa, 7 (64%) with HIV, were receiving clofazimine (100 mg daily) at enrollment, of which 82% received clofazimine for more than 8 weeks prior to pharmacokinetic evaluation. Nine (82%) women continued treatment postpartum. Peak plasma concentrations and area-under-the-concentration-time-curve over 12 hours were comparable to historical clofazimine pharmacokinetic data in nonpregnant women with RR-TB but were approximately 30% higher in the third trimester of pregnancy compared to the postpartum period. Eight women and 8 infants experienced at least one severe adverse event while on study but direct relatedness to clofazimine was considered unlikely. CONCLUSIONS: Overall, antepartum and postpartum clofazimine exposures were comparable to those reported in nonpregnant women with RR-TB. Exposures were lower than expected in the postpartum period, particularly compared with the third trimester of pregnancy.
引用
- Hughes JA, McMorrow F, Brooks KM, et al. Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s. J Infect Dis. 2026. PMID: 41165222. doi:10.1093/infdis/jiaf504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。